October 8, 2009 (Brussels, Belgium) — A new joint statement from a number of professional organizations has identified specific criteria for the clinical diagnosis of the metabolic syndrome, tightening up the definition, which previously differed from one organization to the next .
The statement, published online October 5, 2009 in Circulation, includes the participation of the International Diabetes Federation (IDF), the National Heart, Lung, and Blood Institute (NHLBI), the World Heart Federation, the International Atherosclerosis Society, and the American Heart Association (AHA) and is an attempt to eliminate some of the confusion regarding how to identify patients with the syndrome.
Specifically, the new metabolic-syndrome definition streamlines previous differences related to abdominal obesity as defined by measurements in waist circumference. Substantial disparities existed between the previous IDF and the ATP III definitions of what constituted an excessively large waist circumference, by as much as 8 cm between the two groups, but these have been amended. Now, the criteria for elevated waist circumference are based on population- and country-specific definitions, which, although streamlined, do leave some work to be done, said Eckel.
The new definition relies on different geographic regions, or different countries, to drill down into their own databases in terms of relating waist circumference to risk.
Now, waist circumference is just one of five criteria that physicians can use when diagnosing the metabolic syndrome.
Patients with three of the five criteria--including elevated waist circumference, elevated triglycerides, reduced HDL-cholesterol levels, elevated blood pressure, and elevated fasting-glucose levels--are considered to have the syndrome.
Criteria for Clinical Diagnosis of the Metabolic Syndrome
|Categorical cut points
|Elevated waist circumference
|Population- and country-specific definitions
|Elevated triglycerides (drug treatment for elevated triglycerides is an alternate indicator)
|Reduced HDL cholesterol (drug treatment for reduced HDL cholesterol is an alternate indicator)
|Elevated blood pressure (drug treatment for elevated blood pressure is an alternate indicator)
|Systolic >130 mm Hg and/or diastolic >85 mm Hg
|Elevated fasting glucose (drug treatment for elevated glucose is an alternate indicator)
Notably absent from the joint statement is the American Diabetes Association--there are unresolved scientific issues between the ADA and other associations, including the AHA, regarding the metabolic syndrome.
Specifically, the ADA, as well as the European Association for the Study of Diabetes (EASD), objected to the manner in which the metabolic syndrome was characterized as a risk factor for heart disease or diabetes, arguing that there was no need to diagnose a patient with the syndrome because emphasis should be placed on aggressively treating the individual risk factors.
In 2005, the ADA and EASD issued their own joint statement calling for a critical appraisal of the metabolic syndrome, its designation as a syndrome, and its clinical utility.
Be aware and be well!